Related Experiment Video
Updated: Mar 6, 2026
Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
Published on: April 2, 2020
Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion
1Department of Oncology, Huaihe Hospital of Henan University, Kaifeng, P.R. China.
Abstract:
The gene solute carrier family 34 (sodium phosphate), member 2 (SLC34A2), is a member of the SLC34 family. Increasing evidence suggests that SLC34A2 is involved in the development of many human carcinomas. However, its role in hepatocellular carcinoma (HCC) is still unclear. Therefore, in this study we investigated the role of SLC34A2 in HCC and explored the underlying mechanism. We found that the expression of SLC34A2 is upregulated in HCC cell lines. Knockdown of SLC34A2 obviously inhibited HCC cell proliferation, migration/invasion, and the epithelial-mesenchymal transition (EMT) phenotype. Furthermore, knockdown of SLC34A2 significantly inhibited the expression of phosphorylated PI3K and AKT in HCC cells. Taken together, these results suggest that knockdown of SLC34A2 inhibits proliferation and migration by suppressing activation of the PI3K/AKT signaling pathway in HCC cells, and SLC34A2 may be a potential therapeutic target for the treatment of HCC.
Insights
Solute carrier family 34 (sodium phosphate), member 2 (SLC34A2) is upregulated in hepatocellular carcinoma (HCC). Inhibiting SLC34A2 suppresses HCC cell growth and migration by blocking the PI3K/AKT pathway, suggesting it as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The gene solute carrier family 34 (sodium phosphate), member 2 (SLC34A2) is implicated in various human carcinomas.
- The specific role of SLC34A2 in hepatocellular carcinoma (HCC) remains largely undetermined.
Purpose of the Study:
- To investigate the role of SLC34A2 in HCC development.
- To elucidate the underlying molecular mechanisms of SLC34A2's function in HCC.
Main Methods:
- Analysis of SLC34A2 expression in HCC cell lines.
- Experimental knockdown of SLC34A2 in HCC cells.
- Assessment of cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) markers.
- Evaluation of phosphorylated PI3K and AKT levels.
Main Results:
- SLC34A2 expression was found to be upregulated in HCC cell lines.
- Knockdown of SLC34A2 significantly inhibited HCC cell proliferation, migration, and invasion.
- SLC34A2 knockdown suppressed the epithelial-mesenchymal transition (EMT) phenotype.
- Reduced expression of phosphorylated PI3K and AKT was observed following SLC34A2 knockdown.
Conclusions:
- SLC34A2 knockdown inhibits HCC cell proliferation and migration by suppressing the PI3K/AKT signaling pathway.
- SLC34A2 represents a potential therapeutic target for hepatocellular carcinoma treatment.
More Related Videos
08:50In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
